Table 1.
Therapeutic targets on cancer cells.
| Target molecule | IR700 carrier | TSPC | Cancer | Combination treatment | Tumor model | Ref. |
|---|---|---|---|---|---|---|
| AC133/CD133 | Antibody | AC133-IR700 | Glioblastoma | In vitro and in vivo; ORT | 74 | |
| ꞵ-D-galactose receptor | Ligand | GSA-IR700 | Peritoneal disseminated ovarian cancer | In vitro and in vivo; ORT | 163 | |
| Cadherin-17 | Antibody | ARB102-IR700 | Pancreatic cancer | In vitro and in vivo; s.c. | 171 | |
| CB2R | Ligand | mbc94-IR700 | Brain cancer | In vitro and in vivo; s.c. | 118, 119 | |
| CD146 | Antibody | YY146-IR700 | Melanoma | In vitro and in vivo; s.c. | 67 | |
| CD20 | Antibody | Rituximab-IR700 | B-cell lymphoma | In vitro and in vivo; s.c. | 65 | |
| CD20 | Antibody | NuB2-IR700 | B-cell lymphoma | In vitro and in vivo; s.c. | 66 | |
| CD29 | Antibody | Anti-CD29-IR700 | Melanoma | CTLA4 blockade | In vitro and in vivo; s.c. | 159 |
| CD276 | Fab fragment of antibody | αCD276/Fab-IR700 | Breast cancer | αPD-L1 antibody | In vitro and in vivo; s.c. and lung metastasis | 90 |
| CD44 | Antibody | Anti-CD44-IR700 | Triple-negative breast cancer | In vitro and in vivo; ORT | 72 | |
| CD44 | Antibody | Anti-CD44-IR700 | Oral squamous cell carcinoma | In vitro and in vivo; s.c. | 73 | |
| CD44 | Antibody | Anti-CD44-IR700 | Colon cancer, lung carcinoma, oral carcinoma | PD-1 blockade | In vitro and in vivo; s.c. | 102 |
| CD44 | Antibody | Anti-CD44-mAb-IR700 | Colon cancer, lung carcinoma, oral carcinoma | CTLA4 blockade | In vitro and in vivo; s.c. | 103 |
| CD44 | Antibody | anti-CD44-mAb-IR700 | Colon cancer, lung carcinoma, oral carcinoma | IL-15 | In vitro and in vivo; s.c. | 104 |
| CD47 | Antibody | B6H12-IR700 | Bladder cancer | In vitro and in vivo; s.c. | 75 | |
| CEA | Antibody | 45IR (C2-45 IR700) | Gastric adenocarcin-oma | In vitro and in vivo; s.c. | 12 | |
| CEA | Antibody | Anti-CEA-IR700 | pancreatic cancer | In vitro and in vivo; ORT | 169 | |
| CEA | Antibody | Anti-CEA-IR700 | After bright light surgery in mouse models of pancreatic cancer | In vitro and in vivo; ORT | 57 | |
| CEA | Antibody | Anti-CEA-IR700 | After bright light surgery in PDOX model of pancreatic cancer | In vitro and in vivo; ORT | 170 | |
| CEA | Antibody | DTPA-hMN-14-IR700 | Colorectal cancer | In vitro and in vivo; s.c. | 136 | |
| CEA | Antibody | M5A-700 | Colorectal cancer | In vitro and in vivo; ORT | 58 | |
| c-KIT | Antibody | 12A8-IR700 | Gastrointest-inal stromal tumors | In vitro and in vivo; ORT | 148 | |
| CLA | Antibody | CLA-IR700DX | Mycosis fungoides | In vitro | 161 | |
| DLL3 | Antibody | Rova-IR700 | Lung cancer | In vitro and in vivo; s.c. | 151 | |
| EGFR | Antibody | Cet-IR700 | Head and neck cancer | In vivo/clinical trial | 109, 110 | |
| EGFR | Antibody | Pan-IR700 | Head and neck cancer | In vitro and in vivo; s.c. (subtotal tumor resection model) | 34 | |
| EGFR | Antibody | Pan-IR700 | Bladder cancer | In vitro and in vivo; s.c. | 36 | |
| EGFR | Antibody | Can225-IR700 | Bladder cancer | In vitro and in vivo; s.c. | 38 | |
| EGFR | Antibody | Cet-IR700 or pan-IR700 | Breast cancer, cutaneous squamous cell carcinoma | In vitro and in vivo; ORT | 97 | |
| EGFR | Antibody | Cet-IR700 | Triple-negative breast cancer | In vitro and in vivo; s.c. | 46 | |
| EGFR | Antibody | Pan-IR700 | Breast cancer | In vitro and in vivo; ORT | 50, 100 | |
| EGFR | Antibody | Pan-IR700 | Breast cancer | CyEt-Pan-Duo | In vitro and in vivo; s.c. | 47 |
| EGFR | Antibody | Pan-IR700 | Lung cancer | In vitro and in vivo; ORT | 40 | |
| EGFR | Nanobody | Nanobody-IR700 (7D12, 7D12-9G8) | Head and neck cancer | In vitro and in vivo; ORT | 35 | |
| EGFR | Affibody | ZEGFR:03115-IR700 | Glioblastoma | In vitro and in vivo; s.c. | 33 | |
| EGFR | Affibody | ZEGFR:1907-IR700 | Multidrug resistant colorectal cancer | In vitro and in vivo; s.c. | 141 | |
| GPC1 | Antibody | Miltuximab®-IR700 | Bladder, prostate, brain,ovarian cancer cell lines | In vitro | 130 | |
| GPC3 | Antibody and heavy-chain antibody | HN3-IR700, YP7-IR700 | Hepatocellu-lar carcinoma | In vitro and in vivo; s.c. | 59 | |
| GPC3 | Antibody | YP7-IR700 | Hepatocellu-lar carcinoma | Nanosized albumin-bound paclitaxel | In vitro and in vivo; s.c. | 60 |
| GPA33 | ScFv | A33scFv-R700 | Colorectal tumors | In vitro and in vivo; s.c. | 138 | |
| HER2 | Antibody | Tra-IR700 | Lung metastases | In vitro and in vivo; ORT and lung metastasis | 39, 41 | |
| HER2 | Antibody | Tra-IR700 | Pleural disseminated non-small cell lung carcinoma | In vitro and in vivo; ORT | 42 | |
| HER2 | Antibody | Tra-IR700 | Disseminated peritoneal ovarian cancer | In vitro and in vivo; ORT | 43 | |
| HER2 | Antibody | Tra-IR700 and Per-IR700 |
Gastric cancer | In vitro and in vivo; s.c. | 53 | |
| HER2 | Antibody | Tra-IR700 | Peritoneal dissemination of gastric cancer | In vitro and in vivo; ORT | 54, 55 | |
| HER2 | Antibody | Tra-IR700 | Gastric cancer | 5-FU | In vitro and in vivo; s.c. | 52 |
| HER2 | Nanobody | 1D5-IR700, 1D5-18A12-IR700 | Breast cancer | In vitro and in vivo; ORT | 88 | |
| HER2 | Affibody | HER2 Affibody-IR700 | Breast Cancer | In vitro | 124 | |
| HER2 | Affibody | ZHER2:2395-IR700 | Ovarian cancer | In vitro and in vivo; s.c. | 93 | |
| HGFR | Nanobody | G2c-PS | Hepatocellu-lar, gastric cancer cell lines | In vitro | 91 | |
| HSPG | VLP | AU-011 (IR700) | Primary uveal melanoma | In vitro and in vivo; s.c. (murine) and ORT (rabbit) | 95 | |
| Mesothelin | Antibody | HYP218-IR700 | Cutaneous squamous cell carcinoma stably expressing human mesothelin | In vitro and in vivo; s.c. | 142 | |
| PSMA | Antibody, Diabody, Minibody | PSMA-Db-IR700, PSMA-Mb-IR700, PSMA-IgG-IR700 | Prostate cancer | In vitro and in vivo; s.c. | 89 | |
| PSMA | Antibody | 111 In-DTPA-D2B-IR700 | Prostate cancer | In vitro and in vivo; s.c. | 63 | |
| PSMA | Antibody | Anti-PSMA- IR700 | Prostate cancer | In vitro and in vivo; s.c. | 62 | |
| PSMA | Peptide | PSMA-1-Pc413, PSMA-1-IR700 | Prostate cancer | In vitro and in vivo; s.c. | 64 | |
| PSMA | Small molecule | YC-9 | Prostate cancer | In vitro and in vivo; s.c. | 61 | |
| PD-1 | Antibody | Avelumab-IR700 | Papillary adenocarci-noma of lung | In vitro and in vivo; s.c. | 154 | |
| PDPN | Antibody | NZ-1-IR700 | Malignant pleural mesothelioma | In vitro and in vivo; s.c. and disseminated pleural models | 155 | |
| Pgp | Antibody | Pab-IR700 | Multidrug-resistant cervical cancer | In vitro and in vivo; s.c. | 69 | |
| Pgp | Antibody, Fab fragment | Fab-IR700, Pab-IR700 | Multidrug-resistant cervical cancer | In vitro and in vivo; s.c. | 70 | |
| TROP2 | Antibody | TROP2-IR700 | Biliary & pancreatic cancer | In vitro and in vivo; s.c. | 134 | |
| US28 | Nanobody | VUN100-IR700 | Glioblastoma | In vitro (2D and 3D cultures) | 92 |
CEA: carcinoembryonic antigen; GSA: galactosyl serum albumin; HGFR: hepatocyte growth factor receptor, c-Met; PDOX: patient-derived orthotopic xenograft; TSPC: target-specific photosensitizer conjugate; VLP: virus-like particle; s.c, subcutaneous; ORT, orthotopic